ClinicalTrials.gov ID - NCT05357989
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD).
Topline efficacy data is expected in June.
irpages2.eqs.com/websites/a...
On December 5, 2023, the Company announced the last patient last visit for its PD Phase III study of buntanetap and reported a substantial level of participation with patients enrolled at record pace. Out of 616 total patients screened, 523 were enrolled and 471 completed the trial across 67 sites (43 in the United States and 24 in the European Union). The Company confirmed screen failure (15%) and drop out (9.9%) rates that were below projections.
irpages2.eqs.com/websites/a...
Fingers crossed!
Good news from Annovis (for Alzheimer's)
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Buntanetap for Mental Illnesses?
Annovis Bio - Buntanetap - the share price is down and I wonder why? 
Annovis Bio have published the results of their dose-finding, biomarker study of buntanetap in 14 early Alzheimers & 14 Parkinsons patients
